期刊文献+

趋化因子CCL28在乳腺癌中的表达及意义 被引量:10

Study of CCL28 expression in breast cancer
暂未订购
导出
摘要 背景与目的:目前已知趋化因子在乳腺癌的发生、发展中扮演着重要的角色,但对CCL28在乳腺癌的功能报道较少,本研究旨在探讨趋化因子CCL28在人乳腺癌中的表达情况,并分析其与乳腺癌相关临床病理指标之间的关系。方法:采用免疫组织化学方法检测趋化因子CCL28在150例乳腺癌、相应癌旁正常乳腺组织的表达差异情况;分析乳腺癌中CCL28表达与患者年龄、临床分期、肿瘤直径、淋巴结转移状况、雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)等临床病理指标的相关性。结果:①CCL28在乳腺癌组及癌旁正常乳腺组中均有表达,在乳腺癌组中CCL28的阳性表达率为54.6%,在癌旁正常乳腺组中的阳性表达率为9.3%;CCL28在乳腺癌组的表达明显高于癌旁正常乳腺组,差异有统计学意义(P<0.001)。②CCL28的表达与患者的年龄、肿瘤直径、临床分期、淋巴结转移与否、ER、PR及HER-2的表达等临床病理指标无关(P>0.05)。结论:CCL28在乳腺癌中呈现高表达而在癌旁正常乳腺组织则表达较少,CCL28可能与乳腺癌发生、发展有关。CCL28在乳腺癌中表达的高低与发生淋巴结转移无明显的相关性,CCL28能否作为预测淋巴结转移的指标有待于进一步的研究。 Background and purpose:Chemokines play an important role in breast cancer occurrence and development. However, little about the function of CCL28 in breast cancer is reported. This study was designed to observe and study the expression of chemokine CCL28 in breast cancer, and analyze their association with pathological features of breast cancer.Methods:Expressions of chemokine CCL28 in 150 breast cancer patients were determined by IHC(immunohistochemistry) technique. The corresponding normal breast tissues in paraneoplastic were also detected. The level of CCL28 expression in 150 breast cancer was analyzed whether it was associated with age, cTNM stage, tumor diameter, axillary lymph node status, ER status, PR status and HER-2 status. Results:①CCL28 was highly expressed in both breast cancer and normal breast tissues in paraneoplastic. The positive expression rate of CCL28 in breast cancer was 54.6%and the positive expression rate of CCL28 in normal paraneoplastic breast tissues was 9.3%. Expression of CCL28 in breast cancer was signiifcantly higher than that in normal paraneoplastic breast tissues, there was statistically significance between the two groups(P&lt;0.001). ②The expression of CCL28 was not associated with age, cTNM stage, tumor size, axillary lymph node, ER, PR and HER-2 status(P&gt;0.05). Conclusion:The level of CCL28 expression showed signiifcantly difference between breast cancer and paraneoplastic normal breast tissues. In conclusion, CCL28 may be correlated with breast cancer carcinogenesis and evolvement. The level of CCL28 expression was not signiifcantly correlated with lymph node metastasis. If CCL28 may be a factor to predict lymph node metastasis in breast cancer is worth further studying.
出处 《中国癌症杂志》 CAS CSCD 北大核心 2014年第4期304-309,共6页 China Oncology
关键词 CCL28 乳腺癌 临床病理指标 转移 Breast cancer Clinic pathological factors Metastasis
  • 相关文献

参考文献20

  • 1FACKENTHAL J D, OLOPADE O I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations [ J ] . Nat Rev Cancer, 2007, 7(12): 937-948.
  • 2WANG W, SOTO H, OLDHAM E R, et al. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2) [ J ] . J Biol Chem, 2000, 275(29): 22313-22323.
  • 3PAN J, KUNKEL E J, GOSSLAR U, et al. A novel ehemokine ligand for CCR10 and CCR3 expressed by epithelial ceils in mucosal tissues [ J ] . J Immunol, 2000, 165(6): 2943-2949.
  • 4YOSHIDA R, NAGIRA M, KITAURA M, et al. Secondary lymphoid tissue chemokine is a functional ligand for the CC chemokine receptor CCR7 [ J ] . Biol Chem, 1998, 273(12): 7118-7122.
  • 5ZLOTINK A, YOSHIEO. Chemokines: a new classification system and their role in immunity [ J ]. Immunity, 2000, 12(2): 121-127.
  • 6DEVORA-ROSSI A Z. The biology of chemokines and theirreceptors [ J ] . Annu Rev Immunol, 2000, 18: 217-242.
  • 7SCHWARZ M K, WELLS T N. New therapeutics that modulate chemokine networks [ J ] . Nat Rev Drug Discov, 2002, 1: 347-358.
  • 8AZENSHTEIN E, LUBOSHITS G, SHINA S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promaliguant activity [ J ] . Cancer Res, 2002, 62(4): 1093- 1102.
  • 9SHARMA S, STOLINA M, LUO J, et al. Secondary Lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo [ J ] . J Immunol, 2000, 164: 4558-4563.
  • 10YANG S C, HILLINGER S, RIEDL K, et al. Intratumoral administration of dendritic ceils overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity [ J ] . Clin Cancer Res, 2004, 10: 2891-2901.

共引文献5

同被引文献87

引证文献10

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部